Deutsche Bank Aktiengesellschaft Downgrades Kenvue (NYSE:KVUE) to Hold

Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue (NYSE:KVUE - Free Report) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The firm currently has $24.00 target price on the stock, down from their previous target price of $25.00.

Several other analysts have also issued reports on KVUE. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday. Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Jefferies Financial Group started coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target on the stock. Finally, Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Kenvue currently has a consensus rating of "Hold" and a consensus price target of $22.64.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.13 on Thursday, reaching $22.35. 9,414,905 shares of the company's stock were exchanged, compared to its average volume of 17,651,402. The company has a fifty day moving average of $22.95 and a 200-day moving average of $21.16. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a market capitalization of $42.85 billion, a price-to-earnings ratio of 40.42, a PEG ratio of 2.07 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the prior year, the business posted $0.31 EPS. The business's revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Kenvue will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. The ex-dividend date was Wednesday, November 13th. Kenvue's payout ratio is currently 149.09%.

Hedge Funds Weigh In On Kenvue

Several large investors have recently modified their holdings of the business. Leo Wealth LLC raised its stake in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock valued at $3,507,000 after acquiring an additional 481 shares during the last quarter. Alerus Financial NA increased its position in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock worth $4,426,000 after buying an additional 491 shares during the period. Massmutual Trust Co. FSB ADV increased its position in shares of Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after buying an additional 492 shares during the period. Wolff Wiese Magana LLC increased its position in shares of Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after buying an additional 501 shares during the period. Finally, Marathon Capital Management increased its position in shares of Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company's stock worth $2,722,000 after buying an additional 514 shares during the period. Institutional investors own 97.64% of the company's stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.